QL1706 is a single bifunctional MabPair product, which have shown activity in advanced NSCLC from a phase I study on solid tumors.15 Therefore, this multi-cohort phase II study evaluated QL1706 combined with chemotherapy (with or without bevacizumab) in both EGFR wild-type and mutant advanced NSCLC. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.